Marker Therapeutics, Inc.
For the period ended Dec 31, 2025. Filed Mar 18, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 18, 2026
MRKR$0.99+10.9%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Operations
| | | | | | | |
|---|---|---|---|---|---|---|
| · · For the Years Ended | ||||||
| · · December 31, | ||||||
| · · 2025 · · 2024 | ||||||
| Revenues: | | | | | | |
| Grant income | | $3,546,669 | | $6,591,080 | ||
| Total revenues | | 3,546,669 | | 6,591,080 | ||
| Operating expenses: | | | | | | |
| Research and development | | 11,799,154 | | 13,467,845 | ||
| General and administrative | | 4,184,806 | | 4,241,607 | ||
| Loss on early termination of vendor agreement | | | 453,135 | | | — |
| Total operating expenses | | 16,437,095 | | 17,709,452 | ||
| Loss from operations | | (12,890,426) | | (11,118,372) | ||
| Other income: | | | | | ||
| Interest income | | 594,206 | | 437,010 | ||
| Other income | | | 117,444 | | | — |
| Loss from operations before income taxes | | | (12,178,776) | | | (10,681,362) |
| Income tax (benefit) expense | | | (15,156) | | | 49,953 |
| Net loss | | | (12,163,620) | | | (10,731,315) |
| | | | | | | |
| Net loss per share, basic and diluted | | $(0.79) | | $(1.19) | ||
| | | | | | ||
| Weighted average number of common shares outstanding: | | | | | | |
| Basic | | | 15,310,308 | | | 8,980,207 |
| Diluted | | | 15,310,308 | | | 8,980,207 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.